Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-502, CRTh2 antagonist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-502 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-502, CRTh2 antagonist; oral | DRUG | multiple dose, single schedule |
| Placebo; oral | DRUG | matching placebo |
Key Inclusion Criteria: * Documented history of bronchial asthma diagnosed at least 6 months prior to study start and prior to the age of 40 years. * Body mass index (BMI) of 18 to 35 inclusive. * An ACQ score of ≥ 1.5 at specified time points prior to first dose of study drug. * A best prebronchod...
ARRY-502 is an investigational small molecule being studied for the treatment of persistent asthma. It has also been evaluated in healthy subjects as part of early clinical development. The drug is not approved and remains in clinical trials.
Pfizer, Inc. (NYSE: PFE) is developing ARRY-502. The company has sponsored clinical trials of the drug in healthy subjects and in patients with persistent asthma.
ARRY-502 is in clinical development. It has completed a Phase 1 trial in healthy subjects and a Phase 2 trial in patients with persistent asthma. The drug is investigational and not approved for any use.
ARRY-502 has been studied in two completed trials: NCT01349725, a Phase 1 safety study in healthy subjects, and NCT01561690, a Phase 2 study in patients with persistent asthma. Both trials were conducted in the United States.
No alternative names for ARRY-502 have been disclosed. The drug is referred to solely by its code name ARRY-502 in clinical trial records and by its developer, Pfizer.